What tirzepatide research covers, in brief
Tirzepatide is a synthetic peptide of 39 amino acids, built as an analogue of the naturally occurring hormone glucose-dependent insulinotropic polypeptide (GIP) with a C20 fatty diacid chain attached at a lysine residue in position 20 (NCBI Bookshelf, StatPearls, Farzam and Patel). That fatty acid side chain binds circulating albumin and slows clearance, giving the molecule a half-life near five days and supporting once-weekly subcutaneous dosing.
Eli Lilly markets the compound under two brand names. Mounjaro, approved by the FDA on May 13, 2022 (FDA Drug Approvals database, application 215866), treats type 2 diabetes. Zepbound, approved November 8, 2023, treats chronic weight management in adults with a body mass index of 30 kg/m2 or higher, or 27 kg/m2 or higher with at least one weight-related condition such as hypertension or type 2 diabetes (FDA press announcement, November 2023).
The molecular formula, C225H348N48O68, works out to a molecular weight close to 4,813.6 Da, roughly 17% heavier than semaglutide's 4,113.6 Da despite the broadly similar design of the two peptides (PubChem, CID 156588324).
Mechanism: a dual agonist at GIP and GLP-1 receptors
Native GIP and GLP-1 are both incretin hormones released from the gut after eating, and both stimulate glucose-dependent insulin secretion from pancreatic beta cells. Tirzepatide activates the receptors for both at once, but not equally. Willard et al. measured receptor binding and downstream signaling directly and found that tirzepatide matches native GIP's potency at the GIP receptor, while its potency at the GLP-1 receptor runs about 18-fold lower than native GLP-1 itself (Willard et al., 2020, JCI Insight).
That imbalance appears deliberate. Full-strength GLP-1 receptor activation drives much of the nausea seen with older single-receptor drugs in this class, since GLP-1 receptors sit in brainstem regions tied to the vomiting reflex as well as the hypothalamic regions that reduce hunger. Willard's group proposed that a milder GLP-1 receptor signal paired with strong GIP receptor activation could reduce gastrointestinal side effects at a given dose while the added GIP activity still contributes to weight and glucose effects.
GIP receptor activation independently improves insulin sensitivity in adipose tissue, though the exact reason the combination outperforms single-receptor GLP-1 drugs in head-to-head trial data is still being worked out. That open mechanistic question is part of why tirzepatide receptor-pharmacology papers keep getting published years after the original approval.
Trial evidence: SURPASS and SURMOUNT
The SURPASS program tested tirzepatide for glycemic control first. SURPASS-3 randomized 1,437 adults with type 2 diabetes already on metformin, with or without an SGLT2 inhibitor, to tirzepatide or once-daily insulin degludec. At 52 weeks, HbA1c fell by 1.93, 2.20, and 2.37 percentage points on the 5 mg, 10 mg, and 15 mg tirzepatide doses respectively, against 1.34 points on degludec, and 82% to 93% of tirzepatide participants reached an HbA1c below 7.0% compared to 61% on insulin (Ludvik et al., 2021, The Lancet, n=1,437).
SURMOUNT-1 then tested the same three doses for weight management in 2,539 adults with obesity or overweight who did not have diabetes. At 72 weeks, mean body weight change was -15.0% on 5 mg, -19.5% on 10 mg, and -20.9% on 15 mg, against -3.1% on placebo. Half of the 10 mg group and 57% of the 15 mg group lost at least 20% of body weight, versus 3% on placebo (Jastreboff et al., 2022, New England Journal of Medicine, n=2,539).
The FDA's Zepbound approval also drew on SURMOUNT-2, run in adults with both type 2 diabetes and obesity, a population that has historically lost less weight on incretin therapy than people without diabetes. Across both trials combined, 2,519 participants received Zepbound and 958 received placebo; the FDA's approval summary reports 18% average weight loss at the highest dose in the non-diabetic trial and 12% in the diabetes trial, each measured against placebo at 72 weeks (FDA press announcement, November 2023).
Gastrointestinal side effects, mainly nausea, diarrhea, and constipation, were the most common adverse events across both programs and the leading reason participants stopped treatment, consistent with the receptor mechanism above. The four-to-twenty-week dose escalation schedule built into the label exists specifically to manage this.
Tirzepatide next to semaglutide and retatrutide
Semaglutide activates only the GLP-1 receptor and produced 14.9% mean weight loss at 68 weeks in its own Phase 3 trial, a smaller figure than tirzepatide's 15 mg result over a comparable follow-up window. Our semaglutide research overview covers that trial in full. The gap is one of the pieces of evidence cited for GIP receptor agonism adding independent benefit on top of GLP-1 activity, though the two drugs have not been tested against each other in a single randomized trial.
Retatrutide goes a step further and adds glucagon receptor agonism to the same GLP-1/GIP combination, producing 24.2% mean weight loss in its Phase 2 trial, a larger number than any completed Phase 3 result for tirzepatide. That comparison is not a clean one: retatrutide's figure comes from an earlier, smaller trial phase, which is why Eli Lilly registered a direct head-to-head trial, TRIUMPH-5, in November 2024. Our retatrutide research overview and retatrutide vs tirzepatide comparison cover the trial design differences in more depth, and the retatrutide compound page carries current batch specifications.
Handling and storage for research use
Lyophilized tirzepatide is stable at -20C for extended periods before reconstitution. Once reconstituted with bacteriostatic water, most peptide stability protocols support storage at 2-8C with use within 28 to 30 days, though the certificate of analysis for the specific batch should be checked rather than assumed. Our reconstitution guide covers the general steps, and the dosing calculator converts a stated concentration into volume per unit for protocol planning.
Repeated freeze-thaw cycling degrades peptide integrity, so aliquoting a reconstituted vial into single-use portions before refrigeration is standard practice rather than drawing from the same vial across several weeks. Keep vials shielded from direct light, since peptide bonds are vulnerable to photodegradation over long storage periods, and log the reconstitution date on the vial so no one has to guess how old an aliquot is.
Because tirzepatide is a marketed drug with a published sequence and mass, a certificate of analysis showing HPLC purity above 99% and a mass spectrometry result matching the roughly 4,813.6 Da molecular weight is the baseline check before any batch enters a protocol.
Sourcing tirzepatide for research in Indonesia
Indonesia's tropical climate is the practical complication for any peptide shipment, tirzepatide included. Ambient temperatures in Jakarta, Surabaya, and Bali regularly exceed 28C, well above the 2-8C range that reconstituted peptide stability data assumes, so a shipment that loses cold-chain integrity between courier handoff and lab freezer carries a real degradation risk rather than a theoretical one.
Importers of research and laboratory-use peptide compounds in Indonesia operate under oversight from BPOM (Badan Pengawas Obat dan Makanan); researchers should confirm current documentation requirements directly with BPOM rather than relying on a supplier summary. Our storage guide for tropical climates covers humidity and heat exposure in more detail.
Zurich Biotech ships with insulated cold packs and tracked couriers to Bali, Jakarta, Surabaya, Yogyakarta, and Bandung, but storage discipline after delivery still determines whether a compound arrives usable weeks later. A freezer that cycles above -15C during a power outage, or a courier box left on a hot doorstep for a few hours, can undo the upstream cold chain in a single afternoon.